Mylan Receives Approval for Tamoxifen Citrate Tablets

PITTSBURGH, Feb 21, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg.

Tamoxifen Citrate is the generic version of AstraZeneca's Nolvadex®, which is indicated for the treatment of metastatic breast cancer.

Mylan will manufacture the product in its Puerto Rico facility and will launch the product immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription products. Mylan has two operating segments that market an extensive line of generic and branded products through four business units: Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc. For more information about Mylan, visit www.mylan.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. We refer you to the risk factors and other disclosures contained in our periodic SEC filings. We undertake no duty to update our forward-looking statements, even though our situation may change in the future.

CONTACT: For Mylan Laboratories Inc.
Kris King, 412/232-0100